News

Pharmaceutical firm Teva has received FDA approval for the Abbreviated New Drug Application (ANDA) to market Tri-Lo Sprintec, a generic version of Ortho McNeil Janssen’s oral contraceptive, Ortho

Shire has announced the results of Phase 3b study of Vyvanse (lisdexamfetamine dimesylate) CII that showed significant efficacy at 14 hours after administration during a simulated workplace environment

Biogen Idec and Acorda have signed an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS) therapy, in markets outside the US. Fampridine-SR

The European Commission has granted marketing authorisation for AstraZeneca’s oral anti-cancer drug, IRESSA. It is used for the treatment of adults with locally advanced or metastatic non-small cell

CombinatoRx and Neuromed have entered into a merger agreement under which the companies will merge in all-stock transaction. Under the terms of the agreement, CombinatoRx is expected to

Provectus has completed patient enrollment for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is a topical drug for the treatment of dermatologic diseases, including atopic

Board of Directors of Dow has approved a restructuring plan which calls for the shutdown of a number of manufacturing assets, including ethylene and ethylene-derivative assets in its

Repros Therapeutics has an end of phase II meeting scheduled with FDA in September, to discuss a phase III program investigating the use of Proellex in the treatment

Pfizer has discontinued SUN 1122 phase-III trial for the evaluation of Sutent (sunitinib malate) plus Folfiri versus Folfiri alone, for the first-line treatment of metastatic colorectal cancer. Data